For more than three decades, the dominant hypothesis in Alzheimer’s disease research has rested on a single idea: that the ...

A UCL-led project reducing MRI scan times from around 20 minutes to seven minutes, and a new hearing test, have received funding to be trialled on the NHS to help diagnose dementia.

UK dementia research receives £45M+ in public funding to accelerate early-stage drug discovery, bridging the "valley of death" gap between lab concepts and clinical trials. - Private firms dominate ...

Today, we look at the 'World Alzheimer Report 2026' published by Alzheimer’s Disease International (ADI) in September 2026.

Much of what we know about what causes Alzheimer’s disease – a type of dementia – can be credited to individuals with Down ...

Patients with atypical Alzheimer disease frequently fail to meet the clinical criteria required to receive targeted anti-amyloid therapies.

For decades, research has focused on treating Alzheimer’s disease after symptoms appear. PrevenTRON addresses a different ...

Blocking CXCR3 on immune T cells preserved 40% more memory tissue in Alzheimer’s mice without needing to cross the blood-brain barrier.

One of the hallmark characteristics of Alzheimer’s disease is the abnormal accumulation of amyloid-beta protein in the brain.

Dementia remains one of the toughest challenges in medicine, with limited treatment options despite decades of research.

Despite several uncertainties, TLV’s assessment of the Alzheimer drug Kisunla offers some hope that the treatment may eventually reach Swedish healthcare. That is the view of Linus Jönsson, professor ...

A major global report says Alzheimer's is no longer universally considered untreatable, a significant shift after decades in ...